FDA Alerts

Upadacitinib, an oral JAK1 inhibitor, was approved for the treatment of moderate to severe AD in patients aged 12 years and older.

Abrocitinib received FDA approval for the treatment of moderate to severe AD in adults whose disease was not adequately controlled with other systemic therapies.

Novel biologic tralokinumab, an anti-IL-13 biologic, received FDA approval for the treatment of moderate to severe atopic dermatitis in adults.

The FDA announced that secukinumab received approval for the treatment of active psoriatic arthritis in patients aged 2 years and older.

The FDA announced approval of apremilast for all adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, regardless of disease severity. The approval was based on findings form the ADVANCE trial, a...

The FDA announced the approval of topical ruxolitinib for the treatment of atopic dermatitis in patients aged 12 years and older.

The FDA has announced the approval of halobetasol propionate foam, 0.05%, for use in patients aged 12 years and older.

The FDA announced that it approved an expanded indication for pembrolizumab as monotherapy for the treatment of locally advanced cutaneous squamous cell carcinoma.